ARQT 17.15 ▲ 5.80% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Arcutis Biotherapeutics I...

    NASDAQ: ARQT · Real-Time Price · USD
    17.15
    0.94 (5.80%)
    At close: Sep 05, 2025, 3:59 PM
    17.15
    0.00%
    After-hours: Sep 05, 2025, 07:54 PM EDT
    5.80%
    Bid 16.7
    Market Cap 2.06B
    Revenue (ttm) 263.46M
    Net Income (ttm) -93.27M
    EPS (ttm) -0.74
    PE Ratio (ttm) -23.18
    Forward PE 113.86
    Analyst Buy
    Ask 17.21
    Volume 2,551,768
    Avg. Volume (20D) 1,744,264
    Open 16.24
    Previous Close 16.21
    Day's Range 16.21 - 17.21
    52-Week Range 8.03 - 17.75
    Beta 1.84

    About ARQT

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol ARQT
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for ARQT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Arcutis Biotherapeutics Inc. is scheduled to release its earnings on Nov 5, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    5 months ago
    +12.31%
    Arcutis Biotherapeutics shares are trading higher ... Unlock content with Pro Subscription
    6 months ago
    +8.36%
    Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q4 financial results.
    news image

    3 days ago · seekingalpha.com

    Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript

    Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Citi's Biopharma Back to School Conference September 3, 2025 9:45 AM EDT Company Participants Todd Watanabe - President, CEO & Director Latha Vairavan - Ch...

    news image

    4 days ago · zacks.com

    Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 45.81% as Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 45.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question...

    news image

    1 week ago · zacks.com

    Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?

    Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Foghorn Therapeutics Inc. (FHTX) have performed compared to their sector so far this year.

    news image

    1 week ago · marketbeat.com

    3 Biotech Catalysts Present Major Opportunity

    For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a ...

    news image

    2 weeks ago · seekingalpha.com

    Arcutis: ZORYVE's Multi-Indication Momentum And Margin Expansion Justify A Bullish Re-Rate

    Upgrading ARQT to buy due to explosive revenue growth, improving margins, and strong ZORYVE market adoption across multiple indications. ZORYVE now commands ~41% of non-steroidal topical psoriasis pre...

    news image

    3 weeks ago · zacks.com

    Wall Street Analysts Predict a 44.79% Upside in Arcutis Biotherapeutics (ARQT): Here's What You Should Know

    The average of price targets set by Wall Street analysts indicates a potential upside of 44.8% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question...

    news image

    3 weeks ago · zacks.com

    Are Medical Stocks Lagging Arcutis Biotherapeutics (ARQT) This Year?

    Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Tenet Healthcare (THC) have performed compared to their sector so far this year.

    news image

    1 month ago · seekingalpha.com

    Arcutis Biotherapeutics, Inc. (ARQT) Q2 2025 Earnings Call Transcript

    Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frank Watanabe - Corporate Participant Latha Vairavan - Corporate Participa...

    news image

    4 weeks ago · fool.com

    Arcutis (ARQT) Q2 Revenue Soars 164%

    Arcutis (ARQT) Q2 Revenue Soars 164%

    news image

    1 month ago · zacks.com

    Arcutis Biotherapeutics, Inc. (ARQT) Reports Q2 Loss, Beats Revenue Estimates

    Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.42 per share a year ago.

    Add to Watchlist